Capstone Therapeutics Corporation has set a target of achieving a $100 million revenue run-rate by 2026, with steady progress toward 10% EBITDA margins at its operating subsidiaries. The company reported adding more than $25 million in revenue in 2025 through disciplined, accretive acquisitions, which contributed to a record gross profit and EBITDA for the period. Capstone has expanded its North American footprint, improved demand conditions in key categories, and focused on product innovation, sales execution, and brand expansion to drive organic growth. The company has also taken steps to reduce overhead and improve its EBITDA profile, marking a shift from platform expansion to monetizing scale, with greater visibility on margin expansion, EBITDA growth, and cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-008528), on January 28, 2026, and is solely responsible for the information contained therein.